Targeted-based Nanocarriers for Control of Non-Hodgkin Lymphoma: Current Aspects and Future Perspectives
Main Article Content
Abstract
Oncology faces many challenges with non-Hodgkin lymphoma (NHL) a varied group of lymphatic system
tumors. Immunotherapeutic methods have supplemented or replaced chemotherapy for NHL treatment. Immune
checkpoint inhibitors improve NHL patient outcomes and quality of life. CAR-T cell treatments also enhance
patient prospects. Monoclonal antibody therapy is advancement. Several treatments are still used. Radiation
therapy is a part of this. Multimodal therapy approaches also include stem cell transplantation. The study also
examines treatment resistance and long-term side effects. Nano medicine uses nanomaterial’s to treat cancer.
Oncology entered a new age. This study gives hope for nanomaterial-based NHL treatment. A treatment more
successful, focused and humane.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.